Program
Paltusotine
Also written as “CRN00808”, “Randomized: 40 mg Paltusotine” and “Randomized: 80 mg Paltusotine”.
Its studies are mostly in Acromegaly · Serotonin Syndrome, led by Vertex Pharmaceuticals.
Furthest: phase 3, since Apr 6, 20219 company-led studies, 1 open or runningNext primary completion: Aug 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Vertex Pharmaceuticals | 91 open or running | phase 3since Apr 6, 2021 | Sep 5, 2017 | Aug 2027phase 3 · NCT07087054 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 5, 2017First study: phase 1 study in Healthy VolunteersFirst studyNCT03276858 · 99 enrolled · Australia
- Dec 27, 20182 phase 2 studies in AcromegalyNCT03792555, NCT03789656
- Jan 14, 2020Phase 1 study in Healthy VolunteersNCT04246749 · 11 enrolled · Netherlands
- Feb 6, 2020Phase 2 study in AcromegalyNCT04261712 · 43 enrolled · United States, Brazil, Germany and more
- Apr 6, 2021Phase 3 study in AcromegalyNCT04837040 · 58 enrolled · United States, Argentina, Belgium and more
- Jan 5, 2022Phase 3 study in AcromegalyNCT05192382 · 111 enrolled · United States, Argentina, Brazil and more
- Apr 27, 2022Phase 2 study in Serotonin SyndromeNCT05361668 · 36 enrolled · United States, Argentina, Brazil and more
- Jul 9, 2025Phase 3 study in Serotonin SyndromeNCT07087054 · 141 enrolled · United States, Argentina, Belgium and more
Ahead
- Aug 2027Primary completion: phase 3 study in Serotonin SyndromeNCT07087054
TargetBeta
“An orally bioavailable, nonpeptide somatostatin receptor type 2 (SST2; SSTR2) agonist, ”NCIt, by rule
“Somatostatin receptor 2 agonist”ChEMBL 37, by rule
Studies
All 9 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07087054Serotonin Syndrome · United States, Argentina, Belgium and more | 3 | Active, not recruiting | Aug 2027 | 141 |
| NCT05361668Serotonin Syndrome · United States, Argentina, Brazil and more | 2 | Completed | Mar 7, 2024 | 36 |
| NCT05192382Acromegaly · United States, Argentina, Brazil and more | 3 | Terminated | Jan 20, 2024 | 111 |
| NCT04837040Acromegaly · United States, Argentina, Belgium and more | 3 | Terminated | Jul 10, 2023 | 58 |
| NCT04261712Acromegaly · United States, Brazil, Germany and more | 2 | Terminated | Jun 30, 2026 | 43 |
| NCT04246749Healthy Volunteers · Netherlands | 1 | Completed | Oct 25, 2019 | 11 |
| NCT03792555Acromegaly · United States, Brazil, Greece and more | 2 | Completed | Jul 15, 2020 | 13 |
| NCT03789656Acromegaly · United States, Brazil, Germany and more | 2 | Completed | Aug 3, 2020 | 47 |
| NCT03276858Healthy Volunteers · Australia | 1 | Completed | Apr 30, 2018 | 99 |
How it is read
Names in the registry
- “Paltusotine”, 6 entries
- “CRN00808”, 2 entries
- “Randomized: 40 mg Paltusotine”, 1 entry
- “Randomized: 80 mg Paltusotine”, 1 entry
- “[14C]-CRN00808”, 1 entry
Conditions, from the studies’ own filings
- Acromegaly, 5 studies
- Serotonin Syndrome, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.